This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hansen Medical CEO Discusses Q4 2010 - Earnings Call Transcript

Second, generating record catheter sales and product utilization in the EP market, third fully launching our new Lynx ™, an irrigated ablation catheter in Europe, fourth, gaining unconditional IDE approval from FDA for the artisan clinical trials, fifth, unveiling the new flexible catheter vascular system, at an important endovascular symposium. Sixth, hiring key senior leadership for US commercial sales, engineering, and training in clinical affairs, and seventh, opening our new European headquarters and clinical education center, to start the base to grow our international business in 2011 and beyond.

In achieving these milestones, I’ve been impressed with the ability of the entire organization, including both new and longtime employees, to adopt a new commercial focus and culture of execution that will be critical to our success. And many highlights in the period reflect that commitment and energy. Operating and financial results for Q4 showed encouraging momentum as well. As noted, we posted strong increases in EP utilization, as we delivered record catheter sales and procedures and impressive growth in both, increasing 24% and 34% over Q4 2009 respectively. In addition, we reduced OpEx by $3 million versus Q4 2009, and cut cash used in operations by $5 million versus Q4 2009; a significant achievement considering the high level of development and other non-selling activities undertaken in the period.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,014.19 -111.93 -0.62%
S&P 500 2,111.41 -9.38 -0.44%
NASDAQ 5,081.3140 -16.6620 -0.33%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs